Cargando…
Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D
Vascular endothelial growth factor (VEGF) C and VEGF-D stimulate lymphangiogenesis and angiogenesis in tissues and tumors by activating the endothelial cell surface receptor tyrosine kinases VEGF receptor (VEGFR) 2 and VEGFR-3. These growth factors are secreted as full-length inactive forms consisti...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
2003
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194198/ https://www.ncbi.nlm.nih.gov/pubmed/12963694 http://dx.doi.org/10.1084/jem.20030361 |
_version_ | 1782147648765034496 |
---|---|
author | McColl, Bradley K. Baldwin, Megan E. Roufail, Sally Freeman, Craig Moritz, Robert L. Simpson, Richard J. Alitalo, Kari Stacker, Steven A. Achen, Marc G. |
author_facet | McColl, Bradley K. Baldwin, Megan E. Roufail, Sally Freeman, Craig Moritz, Robert L. Simpson, Richard J. Alitalo, Kari Stacker, Steven A. Achen, Marc G. |
author_sort | McColl, Bradley K. |
collection | PubMed |
description | Vascular endothelial growth factor (VEGF) C and VEGF-D stimulate lymphangiogenesis and angiogenesis in tissues and tumors by activating the endothelial cell surface receptor tyrosine kinases VEGF receptor (VEGFR) 2 and VEGFR-3. These growth factors are secreted as full-length inactive forms consisting of NH(2)- and COOH-terminal propeptides and a central VEGF homology domain (VHD) containing receptor binding sites. Proteolytic cleavage removes the propeptides to generate mature forms, consisting of dimers of the VEGF homology domain, that bind receptors with much greater affinity than the full-length forms. Therefore, proteolytic processing activates VEGF-C and VEGF-D, although the proteases involved were unknown. Here, we report that the serine protease plasmin cleaved both propeptides from the VEGF homology domain of human VEGF-D and thereby generated a mature form exhibiting greatly enhanced binding and cross-linking of VEGFR-2 and VEGFR-3 in comparison to full-length material. Plasmin also activated VEGF-C. As lymphangiogenic growth factors promote the metastatic spread of cancer via the lymphatics, the proteolytic activation of these molecules represents a potential target for antimetastatic agents. Identification of an enzyme that activates the lymphangiogenic growth factors will facilitate development of inhibitors of metastasis. |
format | Text |
id | pubmed-2194198 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2003 |
publisher | The Rockefeller University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-21941982008-04-11 Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D McColl, Bradley K. Baldwin, Megan E. Roufail, Sally Freeman, Craig Moritz, Robert L. Simpson, Richard J. Alitalo, Kari Stacker, Steven A. Achen, Marc G. J Exp Med Article Vascular endothelial growth factor (VEGF) C and VEGF-D stimulate lymphangiogenesis and angiogenesis in tissues and tumors by activating the endothelial cell surface receptor tyrosine kinases VEGF receptor (VEGFR) 2 and VEGFR-3. These growth factors are secreted as full-length inactive forms consisting of NH(2)- and COOH-terminal propeptides and a central VEGF homology domain (VHD) containing receptor binding sites. Proteolytic cleavage removes the propeptides to generate mature forms, consisting of dimers of the VEGF homology domain, that bind receptors with much greater affinity than the full-length forms. Therefore, proteolytic processing activates VEGF-C and VEGF-D, although the proteases involved were unknown. Here, we report that the serine protease plasmin cleaved both propeptides from the VEGF homology domain of human VEGF-D and thereby generated a mature form exhibiting greatly enhanced binding and cross-linking of VEGFR-2 and VEGFR-3 in comparison to full-length material. Plasmin also activated VEGF-C. As lymphangiogenic growth factors promote the metastatic spread of cancer via the lymphatics, the proteolytic activation of these molecules represents a potential target for antimetastatic agents. Identification of an enzyme that activates the lymphangiogenic growth factors will facilitate development of inhibitors of metastasis. The Rockefeller University Press 2003-09-15 /pmc/articles/PMC2194198/ /pubmed/12963694 http://dx.doi.org/10.1084/jem.20030361 Text en Copyright © 2003, The Rockefeller University Press This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/). |
spellingShingle | Article McColl, Bradley K. Baldwin, Megan E. Roufail, Sally Freeman, Craig Moritz, Robert L. Simpson, Richard J. Alitalo, Kari Stacker, Steven A. Achen, Marc G. Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D |
title | Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D |
title_full | Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D |
title_fullStr | Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D |
title_full_unstemmed | Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D |
title_short | Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D |
title_sort | plasmin activates the lymphangiogenic growth factors vegf-c and vegf-d |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2194198/ https://www.ncbi.nlm.nih.gov/pubmed/12963694 http://dx.doi.org/10.1084/jem.20030361 |
work_keys_str_mv | AT mccollbradleyk plasminactivatesthelymphangiogenicgrowthfactorsvegfcandvegfd AT baldwinmegane plasminactivatesthelymphangiogenicgrowthfactorsvegfcandvegfd AT roufailsally plasminactivatesthelymphangiogenicgrowthfactorsvegfcandvegfd AT freemancraig plasminactivatesthelymphangiogenicgrowthfactorsvegfcandvegfd AT moritzrobertl plasminactivatesthelymphangiogenicgrowthfactorsvegfcandvegfd AT simpsonrichardj plasminactivatesthelymphangiogenicgrowthfactorsvegfcandvegfd AT alitalokari plasminactivatesthelymphangiogenicgrowthfactorsvegfcandvegfd AT stackerstevena plasminactivatesthelymphangiogenicgrowthfactorsvegfcandvegfd AT achenmarcg plasminactivatesthelymphangiogenicgrowthfactorsvegfcandvegfd |